Despite modern high-throughput sequencing, the genetic cause of most rare movement disorders remains unclear. A research team ...

Add Yahoo as a preferred source to see more of our stories on Google. When we think of movement disorders, the tremors associated with Parkinson’s disease are probably what first spring to mind.

New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for ...

Despite modern high-throughput sequencing, the genetic cause of most rare movement disorders remains unclear. A research team ...

Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...

Oct. 14 (UPI) --A new award will help early career researchers who study dystonia, the Michael J. Fox Foundation announced Tuesday. The new Bachmann-Strauss Early Career Award is a two-year, $150,000 ...

Imagine your doctor prescribing you a shot of vodka or whiskey to bring you some relief. Well, a new study out of Boston shows the promise of an alcohol-mimicking drug for patients with the ...

US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral ...

Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill, VIM0423. This takes the company’s total funding ...

New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s diseaseFirst ...